Correction: The Impact of Bevacizumab (Avastin) on Survival in Metastatic Solid Tumors - A Meta-Analysis and Systematic Review.

Autor: Limor Amit, Irit Ben-Aharon, Liat Vidal, Leonard Leibovici, Salomon Stemmer

Publikováno v: PLoS ONE, Vol 8, Iss 7 (2013)

Externí odkaz: https://doaj.org/article/2936a97819f349ebb7b73b697fd0faec

Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial

Autor: Robin Kate Kelley, Makoto Ueno, Changhoon Yoo, Richard S Finn, Junji Furuse, Zhenggang Ren, Thomas Yau, Heinz-Josef Klümpen, Stephen L Chan, Masato Ozaka, Chris Verslype, Mohamed Bouattour, Joon Oh Park, Olga Barajas, Uwe Pelzer, Juan W Valle, Li Yu, Usha Malhotra, Abby B Siegel, Julien Edeline, Arndt Vogel, Mehmet Akce, Immaculada Ales Diaz, Gustavo Alves, Sumitra Anand, Cagatay Arslan, Jamil Asselah, Eric Assenat, Francine Aubin, Li-Yuan Bai, Yuxian Bai, Susan Bates, Stephen Begbie, Irit Ben-Aharon, Nina Beri, Marie-Luise Berres, Jean-Frederic Blanc, Ivan Borbath, Robert Bordonaro, Giovanni Brandi, Adam Burgoyne, Kritiya Butthongkomvong, Ke Cao, Marcela Carballido, Marcos Camandaroba, Stephan Lam Chang, Jen-Shi Chen, Ming-Huang Chen, Xiaoming Chen, Ashley Cheng, Tai-Jan Chiu, Hye Jin Choi, Hong Jae Chon, Joelle Collignon, Antonio Cubillo Gracian, Sarah Davis, Ricardo Saraiva de Carvalho, D.J.A. de Groot, Anne Demols, Judith De Vos, Maria Diab, Jacob Easaw, Martin Eatock, Rawad Elias, Fredericus Eskens, Alfredo Falcone, Plinio Fernandez, Richard Finn, Fabio Franke, Masayuki Furukawa, Olumide Gbolahan, Karen Geboes, Keri-Lee Geneser, Zhimin Geng, Ravit Geva, Roopinder Gillmore, Thorsten Goetze, Hongfeng Gou, Julieta Grasselli, Shanzhi Gu, Mahmut Gumus, Nadia Haj Mohammad, Chunyi Hao, Hakan Harputluoglu, Hassan Hatoum, Volker Heinemann, Wang Kwong Ho, Chiun Hsu, Ayala Hubert, Juneul Hwang, Mevlude Inanc, Soledad Iseas, Vaishnavi Jeyasingam, Paula Jimenez Fonseca, Warren Joubert, Jitlada Juengsamarn, Diego Kaen, Masahi Kanai, Stefan Kasper-Virchow, Ghazaleh Kazemi, Fergal Kelleher, Robin Kelley, Jin Won Kim, Jong Gwang Kim, Ana Beatriz Kinupe Abrahao, Heinz Klumpen, Mark Kochenderfer, Fatih Kose, Ho Ching Lam, Choong-kun Lee, Hyun Woo Lee, Margaret Lee, Myung Ah Lee, Wai Man Sarah Lee, Samuel Le Sourd, Dongliang Li, Wei Li, Houjie Liang, Tingbo Liang, Chun Sen Lim, Brian Lingerfelt, Charles Lopez, John Low, Teresa Macarulla Mercade, David Malka, Yimin Mao, Gianluca Masi, Steven McCune, Ray McDermott, Elaine McWhirter, Guillermo Mendez, Michele Milella, Tomonori Mizutani, Camila Moniz, Luisa Morales, Andres Jesús Munoz Martin, Bruno Nervi, Nuttapong Ngamphaiboon, Sang Cheul Oh, Berna Oksuzoglu, Darryl Outlaw, Mustafa Ozguroglu, Ozgur Ozyilkan, Claudio Painemeal, Yueyin Pan, Chuang Peng, Caroline Petorin, Denis Pezet, Derek Power, Shukui Qin, Aflah Roohullah, Hyewon Ryu, Pamela Salman, Rita Sasidharan, Taroh Satho, Kornelius Schulze, Martin Scott-Brown, Ruben Segovia, Thomas Seufferlin, Salvatore Siena, Isabelle Sinapi, Cristina Smolenschi, Tianqiang Song, Aumkhae Sookprasert, Nopadol Soparattanapaisarn, Naureen Starling, Stacey Stein, Salomon Stemmer, Haichuan Su, Rie Sugimoto, Thatthan Suksombooncharoen, Vincent Tam, Ai Lian Tan, Chih Kiang Tan, Suebpong Tanasanvimon, Giuseppe Tonini, Giampaolo Tortora, Akihito Tsuji, Rodrigo Uribe, Marino Venerito, Helena Verdaguer Mata, Ana Paula Victorino, James Wade, Dirk Thomas Waldschmidt, Lu Wang, Wan Zamaniah Wan Isahk, Harpeet Wasan, Rui Weschenfelder, Chun Yin Wong, Yoke Fui Wong, Suayib Yalcin, Patricio Yanez Weber, Xuezhong Yang, Hisateru Yasui, Ozan Yazici, Chia-Jui Yen, Jieer Ying, Wenchang Yu, Haitao Zhao

Publikováno v: The KEYNOTE-966 Investigators, Kelley, R K, Ueno, M, Yoo, C, Finn, R S, Furuse, J, Ren, Z, Yau, T, Klümpen, H-J, Chan, S L, Ozaka, M, Verslype, C, Bouattour, M, Park, J O, Barajas, O, Pelzer, U, Valle, J W, Yu, L, Malhotra, U, Siegel, A B, Edeline, J & Vogel, A 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966): a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet
The Lancet, 2023, 401 (10391), pp.1853-1865. ⟨10.1016/S0140-6736(23)00727-4⟩
KEYNOTE-966 Investigators 2023, ' Pembrolizumab in combination with gemcitabine and cisplatin compared with gemcitabine and cisplatin alone for patients with advanced biliary tract cancer (KEYNOTE-966) : a randomised, double-blind, placebo-controlled, phase 3 trial ', The Lancet, vol. 401, no. 10391, pp. 1853-1865 . https://doi.org/10.1016/S0140-6736(23)00727-4
The Lancet, 401(10391), 1853-1865. Elsevier Limited

Background: Biliary tract cancers, which arise from the intrahepatic or extrahepatic bile ducts and the gallbladder, generally have a poor prognosis and are rising in incidence worldwide. The standard-of-care treatment for advanced biliary tract canc

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::67e2bc96e0f72cde5bf243ad704e6b14
https://pure.manchester.ac.uk/ws/files/261634672/Pembrolizumab_in_combination_with_gemcitabine_and_cisplatin_compared_with_gemcitabine_and_cisplatin_alone_for_advanced_biliary...28Mar2023.docx

Abstract CT205: Safety and preliminary activity of naptumomab estafenatox (NAP) and durvalumab in patients with advanced or metastatic solid tumors: interim results from a phase 1b trial

Autor: Ravit Geva, Salomon Stemmer, Ruth Perets, Corinne Maurice-Dror, Eitan Ben-Ami, Ari Raphael, Sanjeev Kumar, Ilana Lorber, Tal Hetzroni Kedem, Scott Z. Fields, Marcel Rozencweig, Talia Golan

Publikováno v: Cancer Research. 83:CT205-CT205

Background: NAP is a chimeric protein composed of a superantigen (SAg) and a Fab targeting the common tumor antigen 5T4. Its therapeutic effect is associated with activation, expansion and tumor infiltration of SAg-binding specific T cells. Durvaluma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::877d9525ae22c7b36d417a9de361021b
https://doi.org/10.1158/1538-7445.am2023-ct205

Targeting HER2 mutant advanced biliary tract cancers with neratinib: results from the SUMMIT ‘basket’ trial

Autor: James Harding, Sarina Piha-Paul, Ronak Shah, Jessica Murphy, James Cleary, Geoffrey Shapiro, David Quinn, Irene Braña, Victor Moreno, Mitesh Borad, Sherene Loi, Iben Spanggaard, Haeseong Park, James Ford, Monica Arnedos, Salomon Stemmer, Christelle de la Fouchardiere, Christos Fountzilas, Jie Zhang, Daniel DiPrimeo, Casey Savin, S. Duygu Selcuklu, Michael Berger, Lisa Eli, Funda Meric-Bernstam, Komal Jhaveri, David Solit, Ghassan K Abou-Alfa

HER2 mutations are infrequent genomic events in biliary tract cancers (BTCs). Neratinib, an irreversible, pan-HER, oral tyrosine kinase inhibitor, interferes with constitutive receptor kinase activation and has activity in HER2-mutant tumours. SUMMIT

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::b700187bbc235ce424c878694ad5b456
https://doi.org/10.21203/rs.3.rs-1576467/v1

Effect of primary tumor side on survival outcomes in untreated patients with metastatic colorectal cancer when selective internal radiation therapy is added to chemotherapy : combined analysis of two randomized controlled studies

Autor: Peter Gibbs, Volker Heinemann, Navesh K. Sharma, Julien Taieb, Jens Ricke, Marc Peeters, Michael Findlay, Bridget Robinson, Christopher Jackson, Andrew Strickland, Val Gebski, Mark Van Buskirk, Huaqing Zhao, Guy van Hazel, Michael Brown, Matthew Burge, Giuseppe Cardaci, Stephen Clarke, Paul Eliadis, Tom Ferguson, Vinod Ganju, Philip James, Chris Karapetis, Winston Liauw, Gavin Marx, Marco Matos, Louise Nott, Nick Pavlakis, Alex Powell, Timothy Price, David Ransom, Eva Segelov, Jenny Shannon, Nimit Singhal, Euan Walpole, Michel Craninx, Thierry Delaunoit, Amélie Deleporte, Michel Ferrante, Karen Geboes, Alain Hendlisz, Koen Hendrickx, Marc De Man, Els Monsaert, Veerle Moons, Marc Polus, Eveline Boucher, Jacques Balosso, Patrick Chevallier, Samy Louafi, Marc Pracht, Christine Rebischung, Denis Smith, Eric Terrebonne, Harald-Robert Bruch, Gerald Gehbauer, Thomas Helmberger, Yon-Dschun Ko, Hendrik Kröning, Frank Lammert, Arnd Nusch, Stefan Pluntke, Karsten Ridwelski, Jorge Riera-Knorrenschild, Hanno Riess, Jorge Ramon Riera, Tilmann Sauerbruch, Klemens Scheidhauer, Oliver Stötzer, Klaus Tatsch, Ursula Vehling-Kaiser, Thomas Vogl, Alex Beny, Ravit Geva, Einat Shacham-Shmueli, Salomon Stemmer, Thomas Tichler, Ido Wolf, Bruna Angelelli, Andrea Martoni, Michael P.N. Findlay, Richard Isaacs, Anne O’Donnell, David Perez, Bridget A. Robinson, Javier Rodríguez, Ruth Vera-Garcia, Pradip Amin, Daniel Bloomgarden, James Bui, James Carlisle, Seungjean Chai, Yi-Jen Chen, Michael Chuong, Andrew Coveler, Francis Facchini, Gary Frenette, Jacob Frick, Michael Garofalo, Benjamin George, Michael Gordon, Seza Gulec, James Hannigan, Matthew Holtzman, Andreas Kaubisch, Adeel Kaiser, Todd Kooy, Steven Limentani, Jeffrey Margolis, Robert Martin, Howard Ozer, Siddarth Padia, William Rilling, Michael Savin, Elyse Schneiderman, Grant Seeger, Navesh Sharma, Stephen Shibata, Randall Smith, Eric Wang, Samuel Whiting, Morteza Aghmesheh, Mathew Burge, Prasad Cooray, Kynan Feeney, Lionel Lim, Madhu Singh, Craig Underhill, Amelie Deleporte, Aurelie Durand, Sandrine Faivre, Aurelie Ferru, Pascal Hammel, Christoph Bremer, Maike De Wit, Hubert Ayala, Norman Heching, Adi Shani, Cristina Granetto, Gianluca Masi, Stefania Mosconi, Gianmauro Numico, Antonio Trogu, Yeul Hong Kim, Han Sae-Won, Chris Jackson, Anne O'Donnell, Maria Fragoso, Iain Tan, Ana Ruiz Casado, Jin Tung Liang, Jin Hwang Liu, Steven Ades, Miklos Auber, Patrick Boland, Charles Bowers, Martin Crain, Kyran Dowling, Renuka Iyer, Lynn Ratner, Federico Sanchez, Patricia Stoltzfus, Mark Westcott

Publikováno v: Clinical colorectal cancer

The primary tumor side is emerging as a prognostic factor for patients with liver metastatic colorectal cancer (mCRC). In a combined analysis of data from 2 randomized studies, the addition of selective internal radiation therapy to first-line chemot

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::571cccccf3d6dee219ad94de3bda37e6
https://hdl.handle.net/10067/1553790151162165141